Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN): a Retrospective Study of Patients Diagnosed in France From 2000 to 2013
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 86
- 主要终点
- description of the efficacy of treatments for BPDCN
研究概览
简要总结
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease characterized by an aggressive clinical behavior and a poor prognosis. It predominantly affects elderly males with an average age of 67 years at diagnosis and the affected organs are usually the skin, bone marrow, lymph nodes and the central nervous system. Patients with BPDCN have poor outcomes with median overall survival (OS) ranging in the largest series of patients from 8 to 12 months.
Patient care must be defined in this pathology. Despite 40%-90% complete remission (CR) rates after initial chemotherapy, relapses are almost inevitable.
The investigators have developed a national network to collect clinical and biological data of French patients diagnosed with BPDCN.
研究设计
- 研究类型
- Observational
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN) from January 2000 to June 2013 in France.
- •Diagnosis should be established by hematology laboratory of French blood Agency of Bourgogne Franche-Comté and/or by anatomopathological analysis (realized in local centres or by Tony Petrella at Dijon University Hospital) according to phenotypic and anatomopathological criteria published in the literature.
排除标准
- •No exclusion criteria
结局指标
主要结局
description of the efficacy of treatments for BPDCN
时间窗: from the diagnosis to death or until June 2013, date of end of data collection
Measurement of the overall survival for all patients from the date of diagnostic until death or end of data collection
次要结局
- description of clinical profiles of patients(from the diagnosis to death or until June 2013, end of data collection)
- mean duration of the first remission(from the diagnosis to death or until June 2013, end of data collection)
- complete remission rate(from the diagnosis to death or until June 2013, end of data collection)
- non-responders rate(from the diagnosis to death or until June 2013, end of data collection)
- description of biological profiles of patients(from the diagnosis to death or until June 2013, end of data collection)
- survival without events(from the diagnosis to death or until June 2013, end of data collection)
- time interval between two treatments(from the diagnosis to death or until June 2013, end of data collection)
- mortality without relapse(from the diagnosis to death or until June 2013, end of data collection)